The Corporate Transparency Act (CTA) is a new law that affects small businesses in the U.S., including LLCs, corporations, and professional entities. Its main purpose is to help stop illegal activities like money laundering by making business ownership more...
We would like to remind New York healthcare providers about a significant regulatory aspect that impacts the way private insurers handle medical necessity disputes in New York. This is particularly relevant for those engaged in dealing with insurance audits or...
Recently, home infusion pharmacies have faced formidable challenges stemming from underpayment, untimely payment, and non-payment by major medical plans for infusion therapies. This pervasive issue affects both in-network and out-of-network providers across the...
MEDICAID/OMIG Compliance Policies and Reviews Are More Critical Then Ever Beginning July 2023, and very actively since then, NY Medicaid, through OMIG, has been conducting compliance program reviews to determine if required providers had adopted, implemented, and...
In the recent weeks, the New York State Office of the Medicaid Inspector General (OMIG) has conducted numerous unannounced on-site pharmacy visits as part of their new investigative initiative. At the time of the on-site audit, a letter referring to a Credential...
In February 2023, New York State proposed Senate Bill S4007, which aims to introduce regulatory oversight of certain healthcare transactions involving private equity firms. The proposed law would apply to various healthcare entities, including physician...
In the world of healthcare, where precision and compliance are paramount, pharmacies stand as the vital link between physicians and the patients they serve. Yet, in the complex web of regulations, changing laws, and evolving industry standards, pharmacies must...
The FDA has just granted the pharmaceutical industry a one-year extension on enforcing certain enhanced drug distribution security requirements. With the original compliance deadline set for November 27, 2023, the FDA's decision comes in response to industry...
In a sweeping effort to remain up to date with all applicable federal and NYS laws, regulations and policies concerning your pharmaceutical practice, we write this correspondence with the intention of providing information regarding the updated Medicare and...